US Edition
Published • loading... • Updated
Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Summary by Hastings Tribune
9 Articles
9 Articles
The Billings Gazette+6 Reposted by 6 other sources
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimabNew anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in…
·Billings, United States
Read Full Article
Hastings TribuneReposted by 
The Standard-Journal
The Standard-JournalOllin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
AUSTIN, Texas--(BUSINESS WIRE)--Mar 30, 2026-
·Nebraska, United States
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left0Leaning Right2Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
C 60%
R 40%
Factuality
To view factuality data please Upgrade to Premium
